A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 4, 2016, Pages 865-871

  Ahn, Sang Hoon ^a   Heo, Jeong ^d   Park, Jun Yong ^a   Woo, Hyun Young ^d   Lee, Heon Ju ^e   Tak, Won Young ^f   Um, Soon Ho ^b   Yoon, Ki Tae ^d   Park, Soo Young ^f   Kim, Chang Wook ^c   Kim, Hyung Hoi ^d   Han, Kwang Hyub ^a   Cho, Mong ^d  

^a Yonsei University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Pusan National University School of Medicine   (South Korea)

^e Yeungnam University College of Medicine   (South Korea)

^f Kyungpook National University School of Medicine   (South Korea)

Author keywords

Entecavir; Hepatitis B; Lamivudine

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE; HEPATITIS B(E) ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS RESISTANCE; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; HEPATITIS B, CHRONIC; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOMARKERS; DRUG SUBSTITUTION; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84963877913     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13231     Document Type: Article

References (23)

1. Yeo Y, Gwack J, Kang S et al.. Viral hepatitis and liver cancer in Korea: an epidemiological perspective. Asian Pac. J. Cancer Prev. 2013; 14: 6227-31.
2. Lee DH, Kim JH, Nam JJ et al.. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J. Korean Med. Sci. 2002; 17: 457-62.
3. Yang HI, Yeh SH, Chen PJ et al.. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl. Cancer Inst. 2008; 100: 1134-43.
4. Cheong J. Management of chronic hepatitis B in treatment-naive patients. Korean J. Gastroenterol. 2008; 51: 338-45.
5. Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines: management of chronic hepatitis B. Clin. Mol. Hepatol. 2012; 18: 109-62.
6. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J. Hepatol. 2009; 15: S13-24.
7. Lok ASF, Lai C-L, Leung N et al.. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
8. Liaw Y-F, Sung JJY, Chow WC et al.. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
9. Keeffe EB, Dieterich DT, Han SHB et al.. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin. Gastroenterol. Hepatol. 2006; 4: 936-62.
10. Lai CL, Dienstag J, Schiff E et al.. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003; 15: 687-96.
11. Chang T-T, Lai C-L, Chien R-N et al.. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2004; 19: 1276-82.
12. Lai C-L, Shouval D, Lok AS et al.. Entecavir versus Lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-20.
13. Chang T-T, Gish RG, de Man R et al.. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-10.
14. Chang T-T, Lai C-L, Kew Yoon S et al.. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
15. Heathcote EJ, Marcellin P, Buti M et al.. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-43.
16. Tenney DJ, Levine SM, Rose RE et al.. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 2004; 48: 3498-507.
17. Ide T, Sata M, Chayama K et al.. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol. Int. 2010; 4: 594-600.
18. Lok AS, Zoulim F, Locarnini S et al.. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
19. Safadi R, Xie Q, Chen Y et al.. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic Hepatitis B: results of the primary analysis at Week 24. J. Hepatol. 2007; 46: S196.
20. Gish RG, Lok AS, Chang TT et al.. Entecavir therapy for up to 96 Weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.
21. Heo J, Park JY, Lee HJ et al.. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. Antivir. Ther. 2012; 17: 1563-70.
22. Matsuura K, Michitaka K, Yamauchi K et al.. Characteristics of geographic distributions and route of infection for hepatitis B virus genotype D in Ehime area in western Japan. Hepatol. Res. 2007; 37: 255-62.
23. Lee JM, Ahn SH, Kim HS et al.. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53: 1486-93.